Skip to main content

5α-Réductases: Physiologie et pathologie

5α-reductases=physiology and pathology


Les tissus humains contiennent au moins deux isozymes de la 5α-réductase (5α-R), types 1 et 2 qui diffèrent par: leur localisation chromosomique, leur sensibilité aux inhibiteurs, leur expression tissulaire. La 5α-R2 est l’isozyme impliqué dans la différenciation sexuelle et dans le contrôle de la croissance prostatique. Elle est, dans les tissus où elle est androgéno-dépendante (prostate, peau), un amplificateur de l’action des androgènes Les anomalies de la 5α-R2 sont responsables d’insensibilités (pseudohermaphrodisme) ou d’hypersensibilités aux androgènes: hirsutisme idiopathique hyperplasie bénigne de la prostate.


In most androgen target tissues, the first step of androgen action is the 5α-reduction of testostérone to DHT which binds to the androgen receptor wih an affinity 3 to 4 fold higher than testostérone. Two genes, encoding two isozymes of 5α-reductase (5α-R) have been cloned. The two isoforms, 5α-R1 and 5α-R2 are located on chromosome 5 and 2 respectively and differ in optimal pH, substrate and inhibitor affinities and tissue expression. 5α-R2 is responsible for sexual différenciation. It is the major form expressed in the prostate where it seems necessary for embryonic growth and development. In this tissue, as in human skin, 5α-R2 is stimulated by androgens thus amplifying androgen action. 5α-reductase deficiency results in androgen insensitivity due to abnormal 5α-R2. Affected patients are XY individuals with a very peculiar form of male pseudohermaphroditism: they have feminine genitalia at birth and masculinize at puberty. Different mutations, spannning the whole coding portion of the gene, have been described; correlation between mutations and enzyme activity have led to the tentative localization of the substrate binding site in exon 1 and the cofactor binding site in exon 4. In contrast to androgen insensitivity due to 5α-reductase deficiency, increased 5α-reductase activity can result in androgen hypersensitivity as described in idiopathic hirsutism or benign prostatic hyperplasia. In these case antiandrogen therapy, using 5α-reductase inhibitors, can be considered.


  1. ANDERSSON S., RUSSEL D.W.: Structural and biochemical properties of cloned and expressed human and rat steroid 5a-reductases. Proc. Natl. Acad. Sci. USA, 1990, 87: 3640–3644.

    PubMed  Article  CAS  Google Scholar 

  2. ANDERSSON S., BISCHOP R.W., RUSSELL D.W.: Expression, cloning and regulation of Steroid 5α-reductase, an enzyme essential for Male Sexual différenciation. J. Biol. Chem. 1989, 264: 16249–16255.

    PubMed  CAS  Google Scholar 

  3. ANDERSSON, S., BERMAN, D.M., JENKINS, E.P., RUSSELL, D.W.: Deletion of steroid 5α-reductase 2 gene in male pseudohermaphroditism. Nature, 1991, 354: 159–161.

    PubMed  Article  CAS  Google Scholar 

  4. BRUCHOVSKY N., WILSON J.D.: The conversion of testostérone to 5α-androstane-17β-ol-3-one by rat prostate in vivo and in vitro. J. Biol. Chem. 1968, 243: 2012–2021.

    PubMed  CAS  Google Scholar 

  5. CUSSENOT O., BERTHON PH., BERGER R., MOWSZOWICZ I., TEILLAC P., LE DUC A., CALVO F.: Immortalization of human adult normal prostatic epithelial cells by liposomes containing large T-SV40 gene. J. of Urology, 1991, 143, 881–886.

    Google Scholar 

  6. GEORGE F.W., RUSSELL D.W., WILSON J.D.: Feed-forward control of prostate growth: dihydrotestosterone induces expression of its own biosynthetic enzyme, steroid 5α-reductase. Proc. Natl. Acad Sci. USA. 1991, 88: 8044–8047.

    PubMed  Article  CAS  Google Scholar 

  7. GORMLEY G.J., STONER E., BRUSKEWITZ R.C. ET AL: The effect of finastéride in men with benign prostatic hyperplasia. N. Engl. J. Med. 1992, 327: 1185–1191.

    PubMed  CAS  Google Scholar 

  8. HODGINS, M.: Possible mechanisms of androgen resistance in 5α-reductase deficiency: implication for the physiological role of 5a-reductase. J. Steroid Biochem. 1982, 19: 555–559.

    Article  Google Scholar 

  9. JENKINS, E.P., ANDERSSON, S., IMPERATOMCGINLEY, J., WILSON, J.D., RUSSELL, D.W.: Genetic and pharmacological evidence for more than one human steroid 5α-reductase. J. Clin. Invest. 1992, 89: 293–300.

    PubMed  Article  CAS  Google Scholar 

  10. KUTTENN, F., MOWSZOWICZ, I., SCHAISON, G., MAUVAIS-JARVIS P.: Androgen production and skin metabolism in hirsutism. J. Endocr. 1977, 75: 1977, 83–91.

    PubMed  Article  CAS  Google Scholar 

  11. KUTTENN F., MOWSZOWICZ I., WRIGHT F. ET AL: Male pseudo-hermaphroditism: a comparative study of one patient with 5α-reductase deficiency and three patients with the complete form of testicular feminization. J. Clin. Endocrinol. Metab. 1979,: 1979, 861–865.

    Google Scholar 

  12. MAUVAIS-JARVIS P., MOWSZOWICZ I., KUTTENN F.: Significance of 5α-reductase activity in human sexual differentiation. In Sexual Differentiation: basic and clinical aspects. M. Serio et al Edts, Raven Press New-York, 1984, p.247–260.

    Google Scholar 

  13. MCCONNELL J.D., WILSON J.D., GEORGE F.W., GELLER J., PAPPAS F., STONER E.: finastéride an inhibitor of 5a-reductase, suppresses prostatic dihydrotestosterone in men with benign prostatic hyperplasia. J. Clin. Endocrinol. Metab. 1992, 74: 505–508.

    PubMed  Article  CAS  Google Scholar 

  14. MOORE, R.J., GRIFFIN, J.E., WILSON, J.D.: Diminished 5α-reductase activity in extracts of fibroblasts cultured from patients with familial incomplete male pseudohermaphroditism, type 2. J. Biol. Chem. 1975, 250: 7168–7172.

    PubMed  CAS  Google Scholar 

  15. MOWSZOWICZ I., MELANITOU E., KIRCHHOFFER M.O., MAUVAIS-JARVIS P.: Dihydrotestosterone stimulates 5a-reductase activity in pubic skin fibroblasts. J. Clin. Endocrinol. Metab. 1983, 56: 320–325.

    PubMed  CAS  Google Scholar 

  16. MOWSZOWICZ I., RIAHI M., WRIGHT F., BOUCHARD PH., KUTTENN F., MAUVAIS-JARVIS P.: Androgen receptor in human skin cytosol. J. Clin. Endocrinol. Metab. 1981, 52: 338–344.

    PubMed  CAS  Article  Google Scholar 

  17. PETERSON R.E., IMPERATO-MCGINLEY J., GAUTIER T. AND STURLA E.: Male pseudohermaphroditism due to steroid 5α-reductase deficiency. Amer. J. Med. 1977, 62: 170–191.

    PubMed  Article  CAS  Google Scholar 

  18. SIITERI P.K., WILSON J.D.: testostérone formation and metabolism during male sexual differentiation in the human embryo. J. Clin. Endocrinol. Metab. 1974, 38: 113–125.

    PubMed  CAS  Google Scholar 

  19. THIGPEN A.E., DAVIS D.L., MILATOVICH A. ET AL: Molecular genetics of steroid 5α-Reductase 2 deficiency. J. Clin. Invest. 1992, 90: 799–809.

    PubMed  Article  CAS  Google Scholar 

  20. THIGPEN A.E., RUSSEL D.W.: Four-amino acid segment in steroid 5α-reductase 1 confers sensitivity to finastéride, a competitive inhibitor. J. Biol. Chem. 1992, 267: 8577–8583.

    PubMed  CAS  Google Scholar 

  21. THIGPEN A.E., SILVER R.I., GUILEYARDO J.M., CASEY M.L., MCCONNELL J.D., RUSSEL D.W.: Tissue distribution and ontogeny of steroid 5a-reductase isozyme expression. J. Clin. Invest. 1993, 92: 903–910.

    PubMed  Article  CAS  Google Scholar 

  22. VOIGT W., HSIA S.L.: Further studies on testostérone 5α-reductase of human skin. Structural features of steroid inhibitors. J. Biol. Chem. 1973, 248: 4280–4285.

    PubMed  CAS  Google Scholar 

  23. WILSON J.D., GRIFFIN J.E., RUSSELL D.W.: Steroid 5α-reductase deficiency. Endocr. Rev. 1993, 14: 577–593.

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations


Rights and permissions

Reprints and Permissions

About this article

Cite this article

Mowszowicz, I., Berthaut, I., Mestayer, C. et al. 5α-Réductases: Physiologie et pathologie. Androl. 4, 71–77 (1994).

Download citation

  • Issue Date:

  • DOI:

Mots clés

  • 5α-réductase
  • mécanisme d’action des androgènes
  • différenciation sexuelle
  • prostate
  • hirsutisme

Key words

  • 5α-reductase
  • androgen action
  • sexual différenciation
  • pseudohermaphroditism
  • idiopathic hirsutism
  • prostate